| Literature DB >> 31558862 |
Xue-Ying Zhao1, Jian-Wei Wang2, Yue Yin1, Kai Li1, Miao Zhang1, Fu-Ping Yan1.
Abstract
BACKGROUND: Tong Xie Yao Fang is a representative traditional Chinese prescription for the treatment of liver and spleen deficiency, abdominal pain and diarrhea. It has a unique function in the treatment of gastrointestinal dysfunction including irritable bowel syndrome (IBS), is a common functional bowel disease. Its main symptoms are recurrent abdominal pain, diarrhea, constipation or alternations between diarrhea and constipation. There are obvious differences in metabolites between TCM syndromes. By comparing the body fluid metabolism maps of model animals, metabolomics can discover disease biomarkers, analyze the differences in metabolic pathways and understand the pathological process and the metabolic pathways of substances in the body. Thus, the evaluation of animal models tends to be comprehensive and objective. This may provide further understanding between the interaction between Tong Xie Yao Fang and the IBS model. AIM: To evaluate the effect of Tong Xie Yao Fang on IBS rats by using metabolomics method.Entities:
Keywords: Endogenous metabolites; Irritable bowel syndrome; Liver-spleen disharmony; Metabolomics; Tong Xie Yao Fang
Mesh:
Substances:
Year: 2019 PMID: 31558862 PMCID: PMC6747287 DOI: 10.3748/wjg.v25.i34.5134
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Base peak ion chromatograms in positive ion mode of metabolites in urine of rats treated for 0 d. A: Normal group (K); B: Model control group (M); C: Tong Xie Yao Fang high dose group (G); D: Tong Xie Yao Fang medium dose group (Z); E: Tong Xie Yao Fang low dose group (D).
Figure 4Base peak ion chromatograms in negative ion mode of metabolites in urine of rats treated for 14 d. A: Normal group (K); B: Model control group (M); C: Tong Xie Yao Fang high dose group (G); D: Tong Xie Yao Fang medium dose group (Z); E: Tong Xie Yao Fang low dose group (D).
Figure 5Score plot of metabolites in urine of normal and model rats treated for 0 d. A: Principal component analysis (PCA) score plot (positive ion); B: Orthogonal partial least squares discriminant analysis score plot (positive ion); C: Principal component analysis score plot (negative ion); D: Orthogonal partial least squares discriminant analysis score plot (negative ion). K: Normal group; M: Model control group.
Figure 6Score plots of metabolites in urine of normal and model rats treated for 14 d. A: Principal component analysis score plot (positive ion); B: Orthogonal partial least squares discriminant analysis score plot (positive ion); C: Principal component analysis score plot (negative ion); D: Orthogonal partial least squares discriminant analysis score plot (negative ion). K: Normal group; M: Model control group.
Figure 7Score plot of metabolites in urine of rats treated for 0 d. A: Urine principal component analysis score plot (positive ion); B: Urine orthogonal partial least squares discriminant analysis score plot (positive ion); C: Urine score plot (positive ion); D: Principal component analysis score plot (negative ion); E: Orthogonal partial least squares discriminant analysis score plot (negative ion); F: Urine score plot (negative ion). K: Normal group; M: Model group; G: Tong Xie Yao Fang high dose group; Z: Tong Xie Yao Fang medium dose group; D: Tong Xie Yao Fang low dose group.
Figure 8Score plot of metabolites in urine of rats treated for 14 d. A: Urine principal component analysis score plot (positive ion); B: Urine orthogonal partial least squares discriminant analysis score plot (positive ion); C: Urine score plot (positive ion); D: Principal component analysis score plot (negative ion); E: Orthogonal partial least squares discriminant analysis score plot (negative ion); F: Urine score plot (negative ion). K: Normal group; M: Model control group; G: Tong Xie Yao Fang high dose group; Z: Tong Xie Yao Fang medium dose group; D: Tong Xie Yao Fang low dose group.
Information of potential biomarkers in urine of irritable bowel syndrome model
| 1 | HMDB00187 | 3.854 | 105.04 | C3H7NO3 | 2.00494 | [M + H]+ | L-serine | ↑ | ↓ | ↓ | ↓ |
| 2 | HMDB13198 | 8.663 | 184.04 | C8H8O5 | 4.85675 | [M-H] + | 4-methylgallic acid | ↑ | ↓ | ↓ | ↓ |
| 3 | HMDB00167 | 3.204 | 119.06 | C4H9NO3 | 3.76891 | [M + H]- | L-threonine | ↓ | ↑ | ↑ | ↑ |
| 4 | HMDB00635 | 2.915 | 158.06 | C7H10O4 | 8.66271 | [M-H]- | Succinylacetone | ↑ | ↓ | ↓ | ↓ |
| 5 | HMDB29018 | 1.084 | 228.11 | C10H16N2O4 | 5.22312 | [M + H]+ | Prolyl-hydroxyproline | ↑ | ↓ | ↓ | ↓ |
| 6 | HMDB29136 | 4.445 | 204.11 | C8H16N2O4 | 4.11234 | [M + H]- | Valyl-serine | ↓ | ↑ | ↑ | ↑ |
| 7 | HMDB59808 | 4.954 | 232.02 | C8H8O8 | 2.23843 | [M + H]+ | Acetyl citrate | ↓ | ↑ | ↑ | ↑ |
| 8 | HMDB41413 | 7.827 | 554.20 | C26H24O13 | 9.34210 | [M + H]+ | Marmesin rutinoside | ↑ | ↓ | ↓ | ↓ |
| 9 | HMDB00472 | 1.213 | 220.08 | C11H12N2O3 | 5.13710 | [M + H]- | 5-hydroxy-L-tryptophan | ↑ | ↓ | ↓ | ↓ |
VIP: Variable importance in projection; HMDB: Human metabolic group database.
Information of metabolic pathways involved in urine biomarkers in irritable bowel syndrome model rats referred to Kyoto Encyclopedia of Genes and Genomes
| 1 | L-serine | map00270 | Cysteine and methionine metabolism |
| map00600 | Sphingolipid metabolism | ||
| map04974, map01230, map00260 | Protein digestion and absorption; biosynthesis of amino acid; glycine, serine and threonine metabolism | ||
| 2 | L-threonine | map00750 | Vitamin B6 metabolism |
| map04974, map01230, map00260 | Protein digestion and absorption; biosynthesis of amino acid; glycine, serine and threonine metabolism | ||
| 3 | 5-hydroxy-L-tryptophan | map04726 | Serotonergic synapse |
| map00380 | Tryptophan metabolism |